ABGSC acted as Sole Global Coordinator and Bookrunner in the SEK 80m directed share issue in SynAct Pharma

SynAct Pharma announced the successful completion of a directed issue of 1,600,000 common shares at a price of SEK 50.00 per share, raising proceeds of SEK 80m. The share issue was multiple times over-subscribed and was directed to a number of new professional and specialist investors.
SynAct Pharma intends to use the proceeds from the directed share issue to reach the already announced milestones for its phase IIa studies in Rheumatoid Arthritis (RA), Nephrotic Syndrome and Covid-19 (ARDS), and be able to prepare for and complete a phase IIb study in RA.